03:57 AM EDT, 03/12/2025 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) said late Tuesday it priced an underwritten public offering of nearly 13 million shares at $13.50 each to raise an expected $175 million in gross proceeds.

The company granted underwriters a 30-day option to purchase about 1.9 million additional shares.

The offering is expected to close on Thursday, with the proceeds to fund clinical development of lorundrostat, including research, manufacturing and pre-commercialization activities, the company said.